On October 23, the second phase of the Tonghua Dongbao Recombinant Human Insulin Project produced an annual output of 3,000 kg of freeze-dried powder. Tonghua started production and the Governor of Jilin Province, Han Changfu, attended the ceremony. Previously, the project has passed national GMP certification.
Recently, the national export tax rebate rate for the “Recombinant Human Insulin Lyophilized Powder†has been increased from 5% to 13% in the rate of stimulating the economy and raising export tax rebates. In a few days, Tonghua Dongbao’s recombinant human insulin project was three times. Xilinmen.
Tonghua Dongbao developed the first recombinant human insulin preparation in China in 1998 and was named one of the “Top Ten Chinese Science and Technology Progress News†by 587 academicians of the two academies. Since then, the company has been grinding swords for ten years. While expanding domestic and international markets, it has actively expanded production and enriched dosage forms. At present, the company's recombinant human insulin products have been registered and certified in more than 20 countries, including Russia, Poland, Mexico, Brazil, and Ukraine. There are more than 40 countries and regions that are currently registered and certified. From 2001 to now, With limited production capacity, Tonghua Dongbao insulin freeze-dried powder and preparations achieved export value of nearly US$40 million.
Facing a domestic and international market, Tonghua Dongbao has invested RMB 700 million to implement the second-phase expansion project of an annual production capacity of recombinant human insulin 3000 kg production line. After six years of construction, it successfully achieved a test run and passed the national GMP certification. The logo company has It has become Asia’s largest recombinant human insulin production base and is one of the three largest recombinant human insulin production bases in the world.
According to Li Yikui, chairman of Tonghua Dongbao, genetic recombinant human insulin is a high value-added product for China to participate in global high-end competition and has four core competitiveness. First, high-tech content, enjoy 20 years of patent protection; second, there are large-scale production technology, with cost and cost-effective advantages; third is the advantages of the international market; Fourth, has established an international standard, professional marketing team. In the past ten years, the company has marketed recombinant human insulin series products, recombinant human interleukins and other varieties on the market. Currently there are six recombinant protein drugs such as recombinant human growth hormone and recombinant human interferon that are being clinically studied and reported to the state. There are also five new drugs such as Y-type PEGylated therapeutic bioproducts for the treatment of new biological products. Li Yikui said that the company has reached China's leading and world-class protein drugs, and hopes that the country will support national high-tech pharmaceutical companies in export and medical insurance policies, so that a number of high-tech ethnic enterprises will emerge in China.
Automatic, semi-automatic, manual manifold systems for all kinds medium including oxygen, nitrogen, argon, hydrogen, carbon dioxide, propane, etc.
Series of cryogenic fittings&pipings can meet wide range application for cryogenic industry including aluminum vessels, structure, welding fitting, lap joint stub & end, tee, reducer, 90°/45° elbows, etc.
All kinds of cryogenic valves including Excess flow valve, Check Valves, Pressure Relief Valves, Pressure Regulating Valve, Ball Valves, Filling valve, Rebound Valve , Emergency Valve, Globe Valves, Changeover Valves and more.
All kinds of tanker filling metal hose, tanker filling connections and more
Cryogenic Fitting & Piping,Cryogenic Global Valves,Cut-off Valves,Manifold System,Tanker Filling Connector,Tanker Filling Hose
Wuxi Better Technology Co., Ltd , https://www.btheatexchanger.com